Dr. Roger D. Blevins

• 
  ------------------------------------------------------- - [Cached Version]
  Published on: 6/1/2006    Last Visited: 8/17/2008  

  · Roger Blevins, Pharm.D., President and CEO, Xsira Pharmaceuticals, Inc.;

• 
  Aurora Funds - News & Events - Aurora News - 2005 - [Cached Version]
  Published on: 2/28/2005    Last Visited: 8/28/2008  

  Xsira Pharmaceuticals, which commercialized Transfluor® technology based on research conducted at Duke University, will now focus on its own drug discovery program using a license to Transfluor® technology granted by Molecular Devices. ,€,We are excited to see Molecular Devices, a world-class bioanalytical tools company, step into the role of commercializing Transfluor® technology and managing its further evolution,,€, said Roger Blevins, Pharm.D., President and Chief Executive Officer of Xsira. ,€,Transfluor® technology has proven to be an enabling system for GPCR-based drug discovery at Xsira and many other pharmaceutical companies, and we are confident that Molecular Devices is the best company to ensure its continued success.,€

• 
  Aurora Funds - News & Events - Aurora News - 2005 - [Cached Version]
  Published on: 1/1/2005    Last Visited: 8/28/2008  

  "Norak was founded in 1999 with a two pronged strategy, to scale up its Transfluor(R) technology for licensing to third parties as a revenue generator, while simultaneously using Transfluor to discover its own drug pipeline," commented Dr. Roger D. Blevins, President and CEO of Xsira.

• 
  BIO VentureForum East 2006 - Program - [Cached Version]
  Published on: 1/1/2006    Last Visited: 8/17/2008  

  Roger Blevins, Pharm.D., President and Chief Executive Officer, Xsira Pharmaceuticals, Inc.

• 
  Bio.com - Bioengineering - [Cached Version]
  Published on: 6/5/2001    Last Visited: 1/6/2002  

  ``Highly accurate and flexible cell-based screening systems remain a key to biotech and pharmaceutical drug discovery efforts,'' commented Dr. Roger D. Blevins, President and CEO of Norak. ``The combination of these technologies provides the drug development community with a powerful new assay system for GPCR cell-based screening, and should play a leading role in identification of a significant number of new drug targets,'' added Dr. Jeff Stuckey, CEO of Universal Imaging Corporation.

• 
  Biotechnology Council of New Jersey, Inc. - [Cached Version]
  Published on: 2/16/2005    Last Visited: 6/10/2006  

  * Roger Blevins, Pharm.D., President and CEO, Xsira Pharmaceuticals, Inc.;

• 
  Bt Catalyst - [Cached Version]
  Published on: 7/7/1999    Last Visited: 8/12/2000  

  Roger D. Blevins, Pharm.D., has been named CEO of Norak Biosciences Inc. of Durham.Blevins has nearly 20 years of experience in the pharmaceutical industry and academic research.Prior to joining Norak, he was CEO of Medco Research Inc., which was acquired by King Pharmaceuticals Inc. in February 2000.
  
  Return to contents.

• 
  Business Leads updated 07-08-02 from Business Leader... - [Cached Version]
  Published on: 7/8/2002    Last Visited: 2/17/2003  

  The Research Triangle Chapter of the National Association of Corporate Directors elects Jeffrey Le Rose of Research Triangle Consultants as vice president of marketing; Roger Blevins, president/CEO of Norak Biosciences, Inc., as secretary; and George Alwon, president of Raleigh Consulting Group, as treasurer.

• 
  C21 Ventures Conference - [Cached Version]
  Published on: 3/5/2001    Last Visited: 4/7/2004  

  Roger Blevins, President & CEO, Norak Biosciences Inc.

• 
  Headlines/Breaking News from Triangle Business Journal... - [Cached Version]
  Published on: 6/14/2005    Last Visited: 6/14/2005  

  Norak Biosciences Inc. announced Wednesday the appointment of Roger D. Blevins, as chief executive officer.Blevins has nearly 20 years of experience in the pharmaceutical industry and academic research.

Page:  1 2 3 4 5